High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Raffeld M, Abdullaev Z, Alewine C, Rajan A, Giaccone G, Pastan I, Miettinen M, Hassan R.
Thomas A, et al. Among authors: hassan r.
Oncotarget. 2015 May 10;6(13):11694-703. doi: 10.18632/oncotarget.3429.
Oncotarget. 2015.
PMID: 26028668
Free PMC article.
Clinical Trial.